2021
DOI: 10.1097/mol.0000000000000789
|View full text |Cite
|
Sign up to set email alerts
|

ANGPTL3 as therapeutic target

Abstract: Purpose of review Elevated LDL-C and triglycerides are important risk factors for the development of atherosclerotic cardiovascular disease. Although effective therapies for lipid lowering exist, many people do not reach their treatment targets. In the last two decades, ANGPTL3 has emerged as a novel therapeutic target for lowering plasma LDL-C and triglycerides. Here, an overview of the recent literature on ANGPTL3 is provided, focusing on the therapeutic benefits of inactivation of ANGPTL3 via m… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
26
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 50 publications
(27 citation statements)
references
References 48 publications
1
26
0
Order By: Relevance
“…ANGPTL3 inhibits the activity of endothelial lipase and lipoproteins lipase (LPL), resulting in elevated LDL and triglyceride (TG). 290 Currently, two mechanisms have been found to affect ANGPTL3. A mAb targeting ANGPTL3 called evinacumab was designed to decrease LDL-C, non-HDL-C, and TGs by increasing the activity of LPL and other associated metabolic enzymes.…”
Section: Atherosclerosis Therapiesmentioning
confidence: 99%
“…ANGPTL3 inhibits the activity of endothelial lipase and lipoproteins lipase (LPL), resulting in elevated LDL and triglyceride (TG). 290 Currently, two mechanisms have been found to affect ANGPTL3. A mAb targeting ANGPTL3 called evinacumab was designed to decrease LDL-C, non-HDL-C, and TGs by increasing the activity of LPL and other associated metabolic enzymes.…”
Section: Atherosclerosis Therapiesmentioning
confidence: 99%
“…Hence, inactivating endothelial lipase might serve as potential target, to induce lipid starvation in tumor cells, thereby sensitizing them to cell death mechanisms. On the other hand, ANGPTL3, the lipoprotein lipase inhibitor, serves as one of the major risk factor contributing to increased HDL-C and triglycerides and is overexpressed in various malignancies [ 65 ]. However, little is known about the significance of lipoprotein inhibitors to reducing the risk of breast cancer.…”
Section: Future Possibilities Of Targeting Lipid Metabolism To Reduce...mentioning
confidence: 99%
“…ANGPTL3 has become a new target for the treatment of patients with dyslipidemia. Recent studies have confirmed the safety and effectiveness of using monoclonal antibodies or antisense oligonucleotides to inhibit ANGPTL3, and the goal of lipid regulation has been achieved[ 18 - 20 ]. The current evidence supports that ANGPTL3 inhibits the activity of LPL in a manner dependent on betatrophin activation, and there is consistency between them.…”
Section: Discussionmentioning
confidence: 99%